Selpercatinib in the treatment of medullary and radioiodine-refractory differentiated thyroid cancer with RET mutation (literature review)
Selpercatinib is a novel, highly selective, small-molecule inhibitor of RET kinase that competes with adenosine triphosphate. In experimental models, this drug has demonstrated nanomolar activity against various RET gene alterations, including an acquired resistance mutation in the gatekeeper gene a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2025-03-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/1045 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|